Navigation Links
Hospira Announces U.S. Approval of Generic Docetaxel
Date:3/9/2011

LAKE FOREST, Ill., March 9, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira expects to launch the product later this month.

Hospira's docetaxel is approved for the treatment of a variety of cancers. In 2010, U.S. sales of Taxotere were approximately $1.2 billion.

Unlike original product formulations that require healthcare workers to take a two-step process prior to infusion, Hospira's docetaxel comes in a single-vial formulation that is designed to reduce the number of handling steps in the preparation of the product.

"Hospira's docetaxel will give U.S. cancer patients access to a high-quality, lower-cost alternative to the branded product, offers a differentiated delivery system designed to enhance caregiver safety, and reinforces Hospira's commitment to meet patient and caregiver needs in the oncology space," said Thomas Moore, president, U.S., Hospira.

Hospira will offer 20 mg, 80 mg and 160 mg vials of docetaxel at a 10 mg/mL concentration, the original concentration that customers have used safely for many years. Hospira already markets docetaxel in Europe and Australia.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, regulatory, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
2. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
3. Hospira to Present at Upcoming Investor Conferences
4. Hospira Announces FDA Approval of Topotecan Injection
5. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
6. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
7. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
8. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
9. Hospira to Host Conference Call for Third-Quarter 2010 Results
10. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
11. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Wound care devices and products ... the wound. The industry mainly consists of establishments engaged ... treatment of wounds caused by mechanical, chemical, thermal, and ... such as diabetes, skin related diseases, immunological diseases, and ... was the largest region in the wound care ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... DIEGO , March 29, 2017 Avelas Biosciences, Inc., ... from diagnosis through treatment, today announced that Carmine N. Stengone ... the company at the Needham & Company 16 th Annual ... (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of Turmeric. ... for thousands of years. , "The West has caught on, and has discovered Turmeric, ... Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " The ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):